Ask MAPS Anything

Thank you for your interest in our work! Due to the high volume of inquiries received, we ask that you review this FAQ. It is likely that the resources we share will provide you with the information you are looking for.

If you are in a crisis or if you or any other person may be in danger or experiencing a medical or mental health emergency, immediately call 911 (USA) or your local emergency resources.

Content, materials, products or services described in this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment.  

Clinical Trials

How do I apply to the research study of MDMA-assisted therapy for PTSD?

The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel. MAPS is no longer recruiting for the Phase 3 study. Participants in MAPS trials represent people from diverse backgrounds with historical roots of PTSD originating from various traumas including, but not limited to, interpersonal or sexual harm, adverse childhood experiences, vehicular accidents, combat, and more. The Phase 3 trials are expected to be completed at the end of 2022, and if successful, will be submitted to the FDA for New Drug Approval in 2023.

If you are seeking trials that investigate psychedelic-assisted therapy or alternative treatments, please visit:

Additionally, here is some information on emerging research and alternative treatments for PTSD from 

As we conduct trials to inform our application for approval from the FDA, we continue to train therapists, educate our community, and build the foundation for accessible treatments once they are approved. The best way to receive announcements and updates would be by subscribing to the MAPS Email Newsletter

My zip code is not within range of the MDMA-assisted therapy trials. Can you make an exception?

Please note: MAPS is no longer recruiting for the second, confirmatory Phase 3 study.

Due to the length of the study and the number of visits required for participation, long-distance/international commuting is not an option for study participants. We recognize the magnitude of the need for PTSD treatment and hope that we will be able to include more participants in future studies. The Phase 3 trials are expected to be completed at the end of 2022, and if successful, will be submitted to the FDA for New Drug Approval in 2023. 

If you are interested in seeking more trials that investigate psychedelic-assisted therapy or alternative treatments, please visit:

  1. Clinicaltrials.gov, which lists nearly all clinical trials in the U.S. and 200 countries, 
  2. MAPS Participate in Research Page, and 
  3. Psychedelic.Support’s article “How to Join a Psychedelic Clinical Trial” for more information. 

    

Can I have an update on my application for the study?

The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel. If you would like to follow up about the status of your application, please email recruitment@mapsbcorp.com directly.

The Phase 3 trials are expected to be completed at the end of 2022, and if successful, will be submitted to the FDA for New Drug Approval in 2023. If you would like to receive updates about our work, please consider subscribing to the MAPS Email Newsletter.

Thank you for your interest in getting involved in our research.

 

How do I apply to the expanded access program?
Does MAPS say that 89% of participants in trials are cured of their PTSD?

Absolutely not. There is no known cure for PTSD and no reported clinical study has shown 89% of participants no longer having a PTSD diagnosis after MDMA-assisted therapy.

In MAPP1, 88% of participants had a “clinically significant reduction in symptom severity” as defined in our statistical analysis plan as a 10 point drop in CAPS which was reported in publications and media. We also report the 67% loss of diagnosis in MAPP1 in publications and media.

Is MAPS conducting psilocybin therapy research?

No, MAPS is focused on conducting clinical trials for MDMA-assisted therapy. To seek out volunteer opportunities for psilocybin research, please visit ClinicalTrials.gov.  

If you want to educate yourself about psilocybin research, please scroll down to the psilocybin tab below.

Getting Involved with MAPS

Where can I learn more about the MDMA Therapy Training Program?

Please visit the MDMA Therapy Training Program‘s website to learn more about the program requirements, curriculum, and application process. For any specific questions about the program or your application, please email training@mapsbcorp.com directly.

Are you hiring?

Thank you for your interest in employment at MAPS!  Please visit our Careers page to review any open positions at MAPS, MAPS Public Benefit Corporation, or MAPS Europe.

After you read the full job description, any follow-up questions can be directed to jobs@maps.org or jobs@mapsbcorp.com respectively.

If you’d like to get involved in other ways, MAPS and Zendo Project offer volunteer opportunities for events, webinars, psychedelic harm reduction, and more. Please fill out the volunteer application form for more information on how to get engaged with the MAPS community. 

Do you have internships available?

You can view current internship opportunities at MAPS, as well as the current research-related positions at MAPS Public Benefit Corporation (MAPS PBC).

Please check back regularly for new postings, and sign up for the Email Newsletter and follow us on Facebook and Twitter for announcements about new positions.

Thank you for your interest!

What do I need to do to interview someone for a media opportunity?

To submit a media request, please review maps.org/newsroom and complete this quick form. If you are on a tight deadline, please submit the form then call 831-429-MDMA (6362) x 303; your message will be addressed as quickly as possible M-F 8am-6pm Pacific. 

Please understand that we receive a large number of media requests and are simply not able to accommodate all of them. We will, however, do our best to provide a response to every inquiry as soon as we can. If you are able to include your questions in the form, it is more likely that we can respond.  

How do I invite MAPS to participate in, partner with, or promote my event?

The first step to inviting MAPS’ presence at your event is by filling out maps.org/eventform. Once you submit the form, someone from our events team will get in contact with you directly.

Please note: Promotional requests require no less than 2 weeks notice. All other requests require more time to arrange and should be submitted with at least 4 weeks notice.

Can MAPS promote my work on your website or social media networks?

Please submit your request for promotional support at maps.org/request.

Please note: MAPS appreciates the opportunity to learn more about our community and their projects, though we are unable to respond to all requests due to the high volume of inquiries, which occasionally contain content that does not align with our mission or propose expedited timelines that affect our ability to sustainability address our organization’s current priorities. 

Preparation, Integration, and Counseling

Can you refer me to a list of providers for psychedelic integration services?

We’d like to direct you to Psychedelic Support to seek psychedelic integration services.

Psychedelic Support curates evidence-based educational courses on psychedelic science and a directory of licensed mental health providers. Their network of therapists, counselors, holistic doctors, MDs, and integration consultants offer online and in-person services for transformational preparation, psychedelic/plant medicine integration, psychological and physical health, and personal growth. Please note that these licensed professionals do not directly provide psychedelic therapy.

Policy & Advocacy

Medicalization, decriminalization, and legalization? What does it all mean?

MAPS has taken a novel and multi-pronged approach to its mission of developing and supporting medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Medicalization describes the lengthy process of studying currently-illegal substances to determine if they hold benefit for specific conditions, then conducting clinical trials to determine safety and efficacy, then finally submitting a New Drug Application to the FDA. This is MAPS’ primary approach, but not its only one. 

Legalization affirmatively permits and regulates certain actions in a jurisdiction. Criminal sanctions may or may not be maintained by a legalizing jurisdiction for certain actions; other actions may be regulated or require licensing. Medicalization, over-the-counter oversight, state medical use, and state adult use are just some examples of legalization frameworks used for substances commonly ingested by people. 

Decriminalization removes some or all criminal penalties for an activity from the law of the jurisdiction. It is often used to describe situations in which some governments still decide to implement civil penalties (which would not be considered full decrim) or mandatory education/treatment as alternative (which then technically still is not full decrim because while helpful for very few, still punishment for most). 

 It may still allow for penalties such as fines, mandatory education, or (in the worst cases) forced treatment. Remember, a single jurisdiction is probably subject to multiple layers of law which may be quite different from one another (i.e. a U.S. city is governed by city, county, state and federal controlled substances laws).

Lowest Law Enforcement Priority policies maintain most prohibition laws but declare that law enforcement must deprioritize the enforcement of those laws. These policies are useful in U.S. cities where state or Federal law controls city law, and most of the city-wide psychedelic decriminalization measures adopted since 2019 fall into this category.

MAPS sponsors and guides the conduct of research, including clinical trials to develop psychedelics and marijuana into regulatorily approved medicines. MAPS has also supported holistic drug policy reform since its inception in 1986. As the pace of both psychedelic research and reform efforts in areas of social justice, criminalization, drug policy, and psychedelic regulation hasten, we recommend reading our 2019 Statement: Considerations for the Regulation and Decriminalization of Psychedelic Substances for more on these topics.

Does MAPS support the decriminalization of psychedelics?

Although MAPS is a public charity with limited ability to engage in political action, MAPS has worked toward ending the War on Drugs since our founding in 1986 including through supporting decriminalization of the personal possession and use of drugs. We work with fellow advocates to educate lawmakers, community members, and the public about sensible approaches to drug policy. We have responded to inquiries from legislators and advocates about a dozen bills across the United States; most recently, we have advised on California’s Senate Bill 519, the broadest psychedelic drug policy reform a state legislature has ever seriously considered.

Does MAPS support legalization of psychedelics?

MAPS-sponsored clinical trials of MDMA-assisted therapy for PTSD is just one legalization approach for a single criminalized substance with an identifiable history of human use. As a general policy, MAPS is supportive of compassion over criminalization for people who use drugs, psychedelic or otherwise. Specific policy proposals are evaluated in context to determine our ability to support them. MAPS’ capacity for supporting implementation is greater than its capacity for supporting campaigns, both because of its status as a public charity as well as the small size of our team. For this reason, we focus on building coalition and resources with community organizations to make tangible policy changes in high-impact jurisdictions.

What is MAPS’ position on threshold limits as part of decriminalization efforts?

In short, threshold limits are a complicated and nuanced policy area and are more or less useful depending on how the law is written, the context in which laws are being enforced, and every individual drug user’s circumstances. For that reason, MAPS believes decriminalization without threshold limits is a good starting place and the next best option is a set of threshold limits that will provide decriminalization for the vast majority of people.

The downside of threshold limits is that they can lead to arrests for people possessing above the permissible amount of a drug. However, not having limits does not mean that people can possess unlimited amounts. Without specified limits, there is an unknown line (an implicit threshold limit) above which law enforcement, prosecutors, and/or courts could determine that the behavior was no longer “personal use and possession” and instead prosecute said possession as distribution, intent to distribute, or manufacturing. Without limits, people who grow, use, and share these substances would be left guessing about how law enforcement might classify them rather than having those numbers clarified in the law.

Is MAPS a non-profit or for-profit?

MAPS was founded in 1986 a non-profit organization governed by its board of directors, bylaws, mission, and principles. MAPS is qualified as exempt from federal income tax as a public charity under Sections 501(c)(3) and 501(a)(1) of the Internal Revenue Code. Since our founding, MAPS donors have given more than $110 million in support of psychedelic research, medical marijuana research, education, and advocacy. MAPS has earned the Guidestar Platinum Seal of Transparency.

Founded in 2014, MAPS Public Benefit Corporation (MAPS PBC) is a wholly-owned subsidiary of MAPS. MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics while prioritizing public benefit above profit. MAPS PBC does not have private investors, so any proceeds from this work will be reinvested in research, education, advocacy, and therapy access for historically marginalized people.

Questions related to Psychedelics

Please note: MAPS’ research is currently focused on the effects of MDMA and marijuana on posttraumatic stress disorder (PTSD). MAPS cannot provide legal, medical, or mental health advice, nor do we advise on the use of any prohibited substance. 

Psilocybin

MAPS’ resources: 

Additional resources: 

Ibogaine

MAPS’ resources:

Additional resources:

LSD

MAPS’ resources:

In the store:

Additional resources:

Ayahuasca

MAPS’ resources:

In the store:

Additional resources:

Contact Us

If the information you are searching for was not included above, you can send your question to the related email address. We thank you in advance for your patience in receiving a response.

MAPS is no longer recruiting for Phase 3 studies.

The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel. Visit clinicaltrials.gov for information about other trials of psychedelic-assisted therapies.